Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer

Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown significant antitumor activity, which has led to clinical evaluation of multiple FGFR inhibitors. Recently, erdafiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Garje, Rohan, An, Josiah, Obeidat, Mohammad, Kumar, Kranthi, Yasin, Hesham A., Zakharia, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648343/
https://www.ncbi.nlm.nih.gov/pubmed/32790011
http://dx.doi.org/10.1634/theoncologist.2020-0334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648343/
https://www.ncbi.nlm.nih.gov/pubmed/32790011
http://dx.doi.org/10.1634/theoncologist.2020-0334

Ejemplares similares